Cardiac Science Awarded Contract With Novation
30 March 2005 - 5:30PM
PR Newswire (US)
Cardiac Science Awarded Contract With Novation Group Purchasing
Organization Serves 2,300 Healthcare Facilities Nationwide IRVINE,
Calif., March 30 /PRNewswire-FirstCall/ -- Cardiac Science, Inc.
(NASDAQ:DFIB), a leading manufacturer of automatic external
defibrillators, today announced that it has been awarded a contract
from Novation, the supply company of VHA Inc. and the University
HealthSystem Consortium (UHC), covering Cardiac Science's patented
Powerheart(R) Cardiac Rhythm Module(R) (CRM(R)) a fully-automatic
therapeutic bedside monitor-defibrillator designed for
medically-supervised environments such as hospitals, outpatient
medical clinics and physician offices. The contract, which was
established under Novation's new technology program, offers access
to this innovative product to 2,300 VHA and UHC acute and non-acute
healthcare facilities located throughout the United States.
Powerheart CRM is the only FDA-cleared therapeutic bedside
defibrillator- monitor on the market that is designed to be
prophylactically attached to at-risk cardiac patients, continuously
monitor their heart rhythms and when clinically appropriate,
automatically and instantly provide lifesaving defibrillation
therapy without the need to wait for intervention by a nurse or
physician. Cardiac Science Chairman and CEO Raymond W. Cohen said,
"The Novation contract provides us with access to a large group of
hospitals and increases awareness of the Powerheart CRM technology
among administrators and other decision makers. As clinical
evidence mounts that suggests this technology may dramatically
increase survival rates of at-risk cardiac patients and potentially
reduce hospitalization costs, we believe that we may achieve
greater penetration in the U.S. hospital market. " About Novation
Based in Irving, Texas, Novation was established in January 1998
through a combination of the supply programs of VHA and UHC, two
national health care alliances. Novation serves the purchasing
needs of more than 2,300 members and affiliates of VHA and UHC.
These organizations used Novation contracts to purchase more than
$23 billion in supplies in 2004. About Cardiac Science Cardiac
Science develops, manufactures and markets a complete line of
Powerheart(R) brand, automated public access defibrillators (AEDs),
and offers comprehensive AED/CPR training and AED program
management services that facilitate successful deployments. The
company makes the Powerheart(R) CRM(R), the only FDA-cleared
therapeutic patient monitor that instantly and automatically treats
hospitalized cardiac patients who suffer life-threatening heart
rhythms. Cardiac Science also manufactures its AED products on a
private label basis for other leading medical companies such as
Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare.
For more information please visit http://www.cardiacscience.com/ or
call (949) 797-3800. This press release includes forward-looking
statements. These statements may be identified by the use of
forward-looking terminology such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "should," or "will," or
the negative thereof or other variations thereon or comparable
terminology. Cardiac Science has based these forward-looking
statements on the current expectations, assumptions, estimates and
projections. While Cardiac Science believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond our
control. Certain factors, including those discussed in Cardiac
Sciences' Annual Report on Form 10-K for the year ended December
31, 2004, under the heading "Risk Factors," may cause the actual
results, performance or achievements to differ materially from any
future results, performance or achievements expressed or implied by
these forward-looking statements. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. We do not undertake any obligation
to update any such statements or to publicly announce the results
of any revisions to any such statements to reflect future events or
developments. Contact: Matt Clawson (Investors), or Michael
Gioffredi Len Hall (Media) Chief Marketing Officer Allen &
Caron Inc Cardiac Science, Inc. (949) 474-4300 (949) 797-3800
DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson,
, or Media, Len Hall, , both of Allen & Caron Inc,
+1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi,
Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800,
Web site: http://www.cardiacscience.com/
Copyright
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Oct 2023 to Oct 2024